Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Guardant Health Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guardant Health Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Guardant Health Inc
NASDAQ:GH
Cost of Revenue
-$274.7m
CAGR 3-Years
-33%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Cost of Revenue
-$8.5B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
0%
Quest Diagnostics Inc
NYSE:DGX
Cost of Revenue
-$6.4B
CAGR 3-Years
1%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
CVS Health Corp
NYSE:CVS
Cost of Revenue
-$316.5B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
Cigna Corp
NYSE:CI
Cost of Revenue
-$206.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Cost of Revenue
-$9.2B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
-9%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Guardant Health Inc's Cost of Revenue?
Cost of Revenue
-274.7m USD

Based on the financial report for Sep 30, 2024, Guardant Health Inc's Cost of Revenue amounts to -274.7m USD.

What is Guardant Health Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-34%

Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for Guardant Health Inc have been -33% over the past three years , -34% over the past five years .

Back to Top